211 related articles for article (PubMed ID: 25855962)
1. Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization.
Wei L; Zhou Y; Qiao C; Ni T; Li Z; You Q; Guo Q; Lu N
Cell Death Dis; 2015 Apr; 6(4):e1714. PubMed ID: 25855962
[TBL] [Abstract][Full Text] [Related]
2. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
[TBL] [Abstract][Full Text] [Related]
3. Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma.
Wei L; Zhou Y; Dai Q; Qiao C; Zhao L; Hui H; Lu N; Guo QL
Cell Death Dis; 2013 Apr; 4(4):e601. PubMed ID: 23598413
[TBL] [Abstract][Full Text] [Related]
4. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization.
Finley LW; Carracedo A; Lee J; Souza A; Egia A; Zhang J; Teruya-Feldstein J; Moreira PI; Cardoso SM; Clish CB; Pandolfi PP; Haigis MC
Cancer Cell; 2011 Mar; 19(3):416-28. PubMed ID: 21397863
[TBL] [Abstract][Full Text] [Related]
5. Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1α-modulated fatty acid metabolism.
Ni T; He Z; Dai Y; Yao J; Guo Q; Wei L
Cell Death Dis; 2017 Jun; 8(6):e2865. PubMed ID: 28594405
[TBL] [Abstract][Full Text] [Related]
6. SIRT3 elicited an anti-Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis.
Xu L; Li Y; Zhou L; Dorfman RG; Liu L; Cai R; Jiang C; Tang D; Wang Y; Zou X; Wang L; Zhang M
Cancer Med; 2019 May; 8(5):2380-2391. PubMed ID: 30993888
[TBL] [Abstract][Full Text] [Related]
7. Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells.
Dai Q; Yin Q; Wei L; Zhou Y; Qiao C; Guo Y; Wang X; Ma S; Lu N
Mol Carcinog; 2016 Aug; 55(8):1275-89. PubMed ID: 26259145
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
[TBL] [Abstract][Full Text] [Related]
9. Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II.
Wei L; Dai Q; Zhou Y; Zou M; Li Z; Lu N; Guo Q
Biochim Biophys Acta; 2013 Jun; 1830(6):3835-45. PubMed ID: 23500080
[TBL] [Abstract][Full Text] [Related]
10. SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production.
Bell EL; Emerling BM; Ricoult SJ; Guarente L
Oncogene; 2011 Jun; 30(26):2986-96. PubMed ID: 21358671
[TBL] [Abstract][Full Text] [Related]
11. SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis.
Srivastava SP; Li J; Kitada M; Fujita H; Yamada Y; Goodwin JE; Kanasaki K; Koya D
Cell Death Dis; 2018 Sep; 9(10):997. PubMed ID: 30250024
[TBL] [Abstract][Full Text] [Related]
12. 4-Hydroxynonenal promotes growth and angiogenesis of breast cancer cells through HIF-1α stabilization.
Li YP; Tian FG; Shi PC; Guo LY; Wu HM; Chen RQ; Xue JM
Asian Pac J Cancer Prev; 2014; 15(23):10151-6. PubMed ID: 25556440
[TBL] [Abstract][Full Text] [Related]
13. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
[TBL] [Abstract][Full Text] [Related]
14. Mild endothelial dysfunction in Sirt3 knockout mice fed a high-cholesterol diet: protective role of a novel C/EBP-β-dependent feedback regulation of SOD2.
Winnik S; Gaul DS; Siciliani G; Lohmann C; Pasterk L; Calatayud N; Weber J; Eriksson U; Auwerx J; van Tits LJ; Lüscher TF; Matter CM
Basic Res Cardiol; 2016 May; 111(3):33. PubMed ID: 27071400
[TBL] [Abstract][Full Text] [Related]
15. NRF2 facilitates breast cancer cell growth via HIF1ɑ-mediated metabolic reprogramming.
Zhang HS; Du GY; Zhang ZG; Zhou Z; Sun HL; Yu XY; Shi YT; Xiong DN; Li H; Huang YH
Int J Biochem Cell Biol; 2018 Feb; 95():85-92. PubMed ID: 29275212
[TBL] [Abstract][Full Text] [Related]
16. Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies.
Yu W; Denu RA; Krautkramer KA; Grindle KM; Yang DT; Asimakopoulos F; Hematti P; Denu JM
J Biol Chem; 2016 Feb; 291(7):3268-79. PubMed ID: 26631723
[TBL] [Abstract][Full Text] [Related]
17. De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment.
Pinterić M; Podgorski II; Sobočanec S; Popović Hadžija M; Paradžik M; Dekanić A; Marinović M; Halasz M; Belužić R; Davidović G; Ambriović Ristov A; Balog T
Free Radic Res; 2018 Jun; 52(6):672-684. PubMed ID: 29683756
[TBL] [Abstract][Full Text] [Related]
18. SIRT3 Enhances Glycolysis and Proliferation in SIRT3-Expressing Gastric Cancer Cells.
Cui Y; Qin L; Wu J; Qu X; Hou C; Sun W; Li S; Vaughan AT; Li JJ; Liu J
PLoS One; 2015; 10(6):e0129834. PubMed ID: 26121691
[TBL] [Abstract][Full Text] [Related]
19. PGC-1α activates SIRT3 to modulate cell proliferation and glycolytic metabolism in breast cancer.
Zu Y; Chen XF; Li Q; Zhang ST; Si LN
Neoplasma; 2021 Mar; 68(2):352-361. PubMed ID: 33231084
[TBL] [Abstract][Full Text] [Related]
20. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
